How to buy NextCure stock

NextCure, Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 69 staff and has a trailing 12-month revenue of around USD$24.4 million.

How to buy shares in NextCure

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for NextCure. Find the stock by name or ticker symbol: NXTC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NextCure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NextCure, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of NextCure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. NXTC shares summary
2. Compare share dealing platforms
3. Is NXTC stock a buy or sell?
4. Stock performance over time
5. Can I short NXTC shares?
6. NextCure's financials
7. Does NextCure pay a dividend?
8. Other common questions

NextCure share price

Use our graph to track the performance of NXTC stocks over time.

NextCure shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$7.91 - USD$44.71
50-day moving average	USD$12.5899
200-day moving average	USD$10.8283
Wall St. target price	USD$23.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.917

Buy NextCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NextCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NextCure, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting NextCure shares

There are currently 1.9 million NextCure shares held short by investors – that's known as NextCure's "short interest". This figure is 5.5% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting NextCure shares can be evaluated.

NextCure's "short interest ratio" (SIR)

NextCure's "short interest ratio" (SIR) is the quantity of NextCure shares currently shorted divided by the average quantity of NextCure shares traded daily (recently around 295587.21461187). NextCure's SIR currently stands at 6.57. In other words for every 100,000 NextCure shares traded daily on the market, roughly 6570 shares are currently held short.

However NextCure's short interest can also be evaluated against the total number of NextCure shares, or, against the total number of tradable NextCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 NextCure shares in existence, roughly 70 shares are currently held short) or 0.0753% of the tradable shares (for every 100,000 tradable NextCure shares, roughly 75 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NextCure.

Find out more about how you can short NextCure stock.

NextCure overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Frequently asked questions

• What percentage of NextCure is owned by insiders or institutions?

  Currently 14.333% of NextCure shares are held by insiders and 74.895% by institutions.

• How many people work for NextCure?

  Latest data suggests 69 work at NextCure.

• When does the fiscal year end for NextCure?

  NextCure's fiscal year ends in December.

• Where is NextCure based?

  NextCure's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705

• What is NextCure's ISIN number?

  NextCure's international securities identification number is: US65343E1082

• What is NextCure's CUSIP number?

  NextCure's Committee on Uniform Securities Identification Procedures number is: 65343E108